All 50 states apply for Trump’s Medicaid most-favoured-nation drug model

President Donald Trump said on Friday, 18 September, that all 50 states, the District of Columbia and Puerto Rico will join the GENEROUS model, the Medicaid experiment that tries to pull selected drug prices down to levels paid in other rich countries. The Centers for Medicare & Medicaid Services later sharpened the claim. Every jurisdiction has applied. Forty states and Puerto Rico have signed agreements. The rest have until 30 September to put a signature on paper.

GENEROUS stands for GENErating cost Reductions fOr U.S. Medicaid. It opened in January 2026 and runs five years. It is voluntary for manufacturers and for states. Participating companies agree to make listed outpatient drugs available at most-favoured-nation prices. States then invoice those companies for supplemental rebates that bring the net Medicaid price into line with a basket of foreign prices. CMS says it will check the figures and will take a share of the rebates by cutting the federal match.

The agency’s press note puts ten-year taxpayer savings at $64.3 billion. The White House Council of Economic Advisers splits a similar pile into $27.6 billion for states and $36.6 billion for the federal government. Those are model outputs, not audited receipts. The contracts with companies are not public in full. Analysts quoted by MedPage Today and STAT made the same point on Friday: the savings number cannot be checked from outside until the drug list and the reference countries are visible.

Health and Human Services Secretary Robert F. Kennedy Jr. called the sign-up a delivery on Trump’s order to end a system that charges Americans more than other countries. CMS Administrator Mehmet Oz stood with them in the Oval Office. Trump told reporters the extra money should let states “invest in other healthcare improvements or something else” and said “this one thing alone should win us the midterms.” That last line is a political claim. The programme itself is a rebate mechanism.

Medicaid patients already pay small co-payments. The fiscal effect, if the rebates arrive at the advertised scale, lands on state budgets and on the federal share, not on the pharmacy counter sticker a beneficiary sees. The industrial effect lands on manufacturers. The administration says it has pricing agreements with more than two dozen firms, including Pfizer, Eli Lilly, Novo Nordisk, AstraZeneca and EMD Serono. Industry groups continue to argue that exporting the lowest foreign price into the U.S. public programme will cut research budgets. That argument is unchanged from last year. What changed on Friday is the map: no state has stayed out of the application pile.

Two dates now matter more than the press conference. 30 September is the signature deadline for the hold-out states. The next CMS monitoring report will show whether invoices actually match the foreign reference prices the model describes. If either date slips, the $64.3 billion figure becomes a slide rather than a ledger line.

The United States still pays more per dose than peer countries for many branded drugs. That fact is not in dispute. Whether GENEROUS closes a useful part of that gap depends on which molecules are in the model, which countries sit in the comparison set, and whether manufacturers treat Medicaid as a sealed channel or raise other U.S. prices to compensate. Friday’s announcement answered only the first operational question: which governments have asked to join.